New Cancer Drug Fund (CDF) guidance issued in January 2026 means more patients could be eligible for adjuvant treatment with combined Olaparib and hormone therapy. Aligned with this, eligibility criteria for genetic test R444 (NICE approved PARP inhibitor treatment) has been updated.
View the CDF January 2026 update
Full information on CDF funding for Olaparib in combination with hormone therapy (OLAP6)
Updated R444 eligibility criteria:
For people with hormone receptor-positive, HER2-negative breast cancer who have received neoadjuvant chemotherapy and have residual invasive cancer in the breast or the resected lymph nodes (non-pathologic complete response) or both at the time of surgery, testing is now available for everyone where there is either a diagnostic or surgical specimen which is confirmed as pathological high grade.
For people with hormone receptor-positive, HER2-negative breast cancer having adjuvant chemotherapy, testing is now available for everyone with a pre-chemotherapy pathological demonstration of at least one positive lymph node.
These represent changes to the 3rd and 4th eligibility criteria for R444.1 in the national genomic test directory (opens in a new tab). The changes will be reflected in an update to the directory expected later in the year.
For guidance on R444 ordering, contact us.